

February 27, 2014

## **Dr. Martin Madaus to be Named Chairman and CEO of Ortho-Clinical Diagnostics (OCD)**

### **Newly Created Role to Begin Pending Close of Acquisition of OCD by The Carlyle Group**

#### **Experienced Diagnostics Executive has Proven Record in Growing Businesses**

WASHINGTON--(BUSINESS WIRE)-- Global alternative asset manager The Carlyle Group (NASDAQ:CG) today announced that Dr. Martin D. Madaus will become Chairman and Chief Executive Officer of Ortho-Clinical Diagnostics ("OCD") subject to the close of Carlyle's acquisition of OCD from Johnson & Johnson, which is expected in mid-2014. Eric Compton, OCD Worldwide President, will continue with the company following the close of the transaction.

Introduced to OCD today during a global employee meeting, Dr. Madaus said, "I am pleased by the opportunity to join Ortho-Clinical Diagnostics and look forward to working with such a talented group of professionals around the world. I am excited at the prospect of leading the organization through its next phase of growth, driven by new product innovation and geographic expansion. Eric and his team have accomplished great things as part of Johnson & Johnson and I look forward to helping transform OCD into a global diagnostics leader as a standalone entity."

Eric Compton, OCD Worldwide President, said, "OCD has made strategic investments in research and development programs over the past few years and the Company is poised for continued success in the future. Together with Martin and the team at Carlyle, we believe OCD is positioned to accelerate growth globally through new product introductions."

Stephen H. Wise, Carlyle Managing Director, said, "As an experienced executive with an exemplary track record of growing businesses, Martin can lead OCD through its transition to an independent company and transformation into a leading diagnostics platform. We believe our long-term partnership with Martin in the in vitro diagnostics industry will create significant value for our investors over the coming years."

Dr. Madaus is the current Executive Chairman of Quanterix's Board of Directors. He most recently served as President, Chairman and Chief Executive Officer of Millipore Corp., which was acquired by Merck KGaA in 2010. Before joining Millipore, Dr. Madaus was President, Chief Executive Officer and Head of North American Operations for Roche Diagnostics Corp.

He also held a number of senior-level sales, marketing and product management positions with Boehringer Mannheim Corp. in both Germany and the United States. In addition to Quanterix, Dr. Madaus is a director at Carlyle portfolio company PPD, Mettler Toledo, and Covidien. He has a doctor of veterinary medicine degree from the University of Munich, Germany and a doctorate in veterinary medicine from the Veterinary School of Hanover, Germany.

The close of the transaction is subject to the fulfillment of certain conditions, including the receipt of applicable anti-trust clearances and other customary closing requirements.

#### **About Ortho-Clinical Diagnostics, Inc.**

Ortho-Clinical Diagnostics, Inc. delivers the high-quality in vitro diagnostic products that give healthcare professionals around the world the knowledge they need to make better treatment decisions sooner. The company serves the global transfusion medicine community with donor screening and blood typing products to help ensure every patient receives blood that is safe, the right type and the right unit. Ortho-Clinical Diagnostics also brings sophisticated information management, testing technologies and automation and interpretation tools to clinical laboratories worldwide to help them run more efficiently and improve patient care. For more information, visit [www.orthoclinical.com](http://www.orthoclinical.com)

#### **About The Carlyle Group**

The Carlyle Group (NASDAQ: CG) is a global alternative asset manager with approximately \$189 billion of assets under management across 118 funds and 100 fund of funds vehicles as of December 31, 2013. Carlyle's purpose is to invest wisely and create value on behalf of its investors, many of whom are public pensions. Carlyle invests across four segments - Corporate Private Equity, Real Assets, Global Market Strategies and Solutions - in Africa, Asia, Australia, Europe, the Middle East, North America and South America. Carlyle has expertise in various industries, including: aerospace, defense & government services, consumer & retail, energy, financial services, healthcare, industrial, real estate, technology & business services, telecommunications & media and transportation. The Carlyle Group employs more than 1,500 people in 34 offices

across six continents.

Web: [www.carlyle.com](http://www.carlyle.com)

Videos: [www.youtube.com/onecarlyle](http://www.youtube.com/onecarlyle)

Tweets: [www.twitter.com/onecarlyle](http://www.twitter.com/onecarlyle)

Podcasts: [www.carlyle.com/about-carlyle/market-commentary](http://www.carlyle.com/about-carlyle/market-commentary)

**The Carlyle Group**

Liz Gill: +1 (202) 729-5385

[Elizabeth.gill@carlyle.com](mailto:Elizabeth.gill@carlyle.com)

Source: The Carlyle Group

News Provided by Acquire Media